Approved indications (who Nucala is for):

• Severe asthma with an eosinophilic phenotype: add-on maintenance therapy in adults and children 6 years and older whose asthma remains uncontrolled on standard inhaled treatments.
• Chronic rhinosinusitis with nasal polyps (CRSwNP): add-on maintenance treatment in adults 18 years and older who still have significant nasal symptoms despite nasal corticosteroids.
• Chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype: add-on maintenance treatment in adults with inadequately controlled COPD and elevated eosinophils; it is not for sudden breathing attacks.
• Eosinophilic granulomatosis with polyangiitis (EGPA): treatment of adults with EGPA.
• Hypereosinophilic syndrome (HES): treatment of adults and children 12 years and older with HES for at least 6 months without an identifiable secondary (non-blood) cause.

Off-label uses and evidence level:

• Clinicians sometimes use mepolizumab off-label for other rare eosinophilic diseases (for example, chronic eosinophilic pneumonia) when standard therapies, usually corticosteroids, are not tolerated or fail.
• Evidence for these off-label uses comes mainly from case reports and small case series rather than large randomized trials, so benefits and risks are less certain, and such use is generally reserved for specialized centers.

Efficacy expectations and time to benefit:

• Severe eosinophilic asthma: many patients have fewer asthma attacks and steroid bursts within the first 1–3 injections (1–3 months), with further improvement over 3–6 months; lung function and symptom control typically improve, but some patients respond only partially.
• CRSwNP: nasal congestion, drainage, and sense of smell often start to improve within a few months, and studies show reduced polyp size and a lower need for sinus surgery or repeated courses of oral steroids.
• EGPA and HES: Nucala usually reduces blood eosinophil counts quickly and, over months, lowers relapse rates and allows tapering of oral steroids in many patients, though some still need additional immunosuppressive therapy.
• COPD with eosinophilic phenotype: reductions in COPD exacerbations are more modest than in asthma and mainly seen in patients with clearly elevated eosinophils; Nucala does not replace inhalers or rescue medications.

Comparison with similar drugs: Compared with long-term oral corticosteroids, Nucala targets eosinophils more specifically and tends to provide similar or better control of eosinophilic disease activity with fewer systemic side effects; among biologics, it is one of several options (such as other anti–IL-5 or anti–IL-4/13 agents), and choice depends on the exact disease, eosinophil levels, coexisting conditions (for example nasal polyps or eczema), dosing schedule, and insurance coverage.

Typical dosing by condition and age (subcutaneous, every 4 weeks):

• Severe eosinophilic asthma: adults and adolescents 12 years and older receive 100 mg every 4 weeks; children 6–11 years receive 40 mg every 4 weeks.
• Chronic rhinosinusitis with nasal polyps (adults ≥18 years): 100 mg every 4 weeks.
• COPD with an eosinophilic phenotype (adults): 100 mg every 4 weeks.
• Eosinophilic granulomatosis with polyangiitis (adult EGPA): 300 mg every 4 weeks, given as three separate 100‑mg injections at least a few centimeters apart.
• Hypereosinophilic syndrome (HES): adults and adolescents 12 years and older receive 300 mg every 4 weeks, also as three 100‑mg injections.

How and where it is given:

• Nucala is injected under the skin (subcutaneously), usually into the thigh or abdomen, or the back of the upper arm if given by a caregiver or healthcare professional.
• For many adults and adolescents (typically ≥12 years), prefilled syringes or autoinjectors can be used at home after proper training; younger children and patients receiving the vial formulation usually get injections from a healthcare professional.
• It can be given with or without food and is scheduled once every 4 weeks on the same calendar day when possible.

Special dosing and administration considerations:

• No weight-based dose adjustments are needed in approved indications; dosing is fixed by age and condition.
• Nucala is not a rescue medicine and should always be used in addition to, not instead of, standard controller and rescue therapies (such as inhaled corticosteroids and bronchodilators for asthma or COPD).
• Oral and inhaled steroids or other immunosuppressants are usually tapered only after clear clinical response to Nucala and under close supervision.

Missed-dose guidance:

• If you self-inject and miss a dose, you or your caregiver should inject it as soon as you remember, then resume your usual every‑4‑weeks schedule; if you do not realize you missed a dose until your next scheduled injection date, just take the next scheduled dose and do not double up.
• If you receive injections at a clinic and miss an appointment, contact the office as soon as possible to reschedule.

Overdose:

• Using more Nucala than prescribed is not known to provide extra benefit and could increase the risk of side effects; if you think you have received too much, contact your prescriber or a poison control center (in the U.S., 1-800-222-1222), and seek emergency care if you have severe symptoms.

Common side effects (usually mild to moderate):

• Injection-site reactions (pain, redness, swelling, itching or burning where the shot was given), which are among the most frequent effects and often lessen over time.
• Headache, back pain, fatigue, and joint or muscle aches; in CRSwNP, throat discomfort and joint pain are more common, and in COPD, back pain, diarrhea, and cough occurred more often than with placebo.
• These effects typically start within a few days of an injection and are usually manageable with simple measures; they rarely require stopping treatment.

Serious or rare adverse effects (seek urgent medical help):

• Allergic/hypersensitivity reactions, including anaphylaxis: symptoms can include hives, rash, itching, flushing, swelling of the face, lips, tongue, or throat, trouble breathing or swallowing, chest tightness, dizziness, or feeling faint; these may occur within hours or be delayed for days after an injection.
• Herpes zoster (shingles) and some other infections have been reported slightly more often; tell your clinician promptly if you develop a painful blistering rash, fever, or other signs of infection.
• Worsening breathing symptoms, chest pain, or signs of vasculitis or organ involvement in EGPA/HES (for example new nerve symptoms, kidney problems) should be evaluated immediately.

Warnings and precautions:

• Not for sudden attacks: Nucala must not be used to treat acute asthma or COPD attacks; you should continue to carry and use your quick-relief inhalers or other rescue medicines.
• Parasitic (helminth) infections: existing helminth infections should be treated before starting Nucala; if a new helminth infection does not respond to standard treatment, Nucala may need to be paused.
• Corticosteroid tapering: do not stop oral or inhaled steroids abruptly when starting Nucala; steroid doses should be reduced slowly under medical supervision to avoid withdrawal and disease flares.
• Pregnancy and breastfeeding: human data are limited; animal studies have not shown clear harm, but the drug crosses the placenta and likely appears in small amounts in breast milk, so clinicians balance the benefits of disease control against uncertain fetal or infant risks.
• Age and organ function: approved pediatric use is limited to asthma (ages ≥6) and HES (ages ≥12); there are no specific dose adjustments for kidney or liver impairment, but experience in severe organ dysfunction is limited, so careful monitoring is advised.

Overall safety profile versus other options: Because Nucala targets IL-5 and eosinophils specifically, it does not cause the broad immune and metabolic side effects seen with long-term oral steroids; in clinical trials, overall rates of common infections and serious adverse events were similar to placebo, making it generally well tolerated when used in appropriate patients.

Reporting side effects and safety updates: Patients should promptly inform their prescriber about any bothersome or unusual symptoms; side effects can also be reported directly to the manufacturer (GlaxoSmithKline) or to the FDA through the MedWatch program (online or by calling 1-800-FDA-1088), where up-to-date safety communications are posted.

Drug and supplement interactions:

• Mepolizumab is a monoclonal antibody cleared mainly by normal protein breakdown pathways, not by liver enzymes such as CYP450, so clinically important interactions with most other medicines are unlikely.
• Formal interaction studies are limited, but no consistent interactions have been identified with common prescription drugs, over‑the‑counter medicines, or supplements; nonetheless, you should always tell your clinician about all medicines, vitamins, and herbal products you use.
• Because Nucala is often used together with inhaled or oral corticosteroids and other asthma or COPD controllers, changes to these drugs (especially steroid dose reductions) should be supervised to avoid flares.

Food, alcohol, and imaging procedures:

• There are no known interactions with specific foods or beverages, and Nucala does not need to be timed with meals.
• The effect of alcohol on Nucala itself is unknown, but heavy alcohol use can worsen many underlying conditions and interact with other medications (such as steroids), so moderation is usually advised.
• No specific interactions are known with imaging contrast agents or common diagnostic procedures; still, inform radiology and lab staff that you are receiving a biologic therapy.

Conditions and co-medications requiring caution:

• Helminth (parasitic worm) infections should be treated before starting Nucala; if you develop such an infection that does not respond to standard therapy, your clinician may pause Nucala until it resolves.
• People with a history of severe allergic reactions to biologic drugs or to mepolizumab or its ingredients should not receive Nucala.
• Patients with chronic or recurrent infections, significant immune compromise, or other serious systemic diseases may still be candidates but require individualized risk–benefit assessment.
• Before starting therapy, doctors may review vaccination status (including shingles vaccination in appropriate adults) and other immunosuppressive medications you are taking.

Monitoring needs:

• No routine dose-related blood pressure, ECG, or organ function monitoring is required beyond usual care, but clinicians often track symptoms, asthma/COPD exacerbations, and blood eosinophil counts to judge response.
• Patients are usually observed for a period after early injections for signs of hypersensitivity or injection reactions, particularly when starting treatment or switching device types.

Q: What conditions is Nucala used to treat?
A: Nucala is used as an add-on treatment for severe eosinophilic asthma in patients 6 years and older, for adults with chronic rhinosinusitis with nasal polyps or COPD with an eosinophilic phenotype, and for adults with EGPA and patients 12 years and older with hypereosinophilic syndrome.

Q: How long does it take for Nucala to start working?
A: Some people notice improved breathing or sinus symptoms after the first few injections (about 1–3 months), but full benefits are usually evaluated after 3–6 months of regular once‑monthly dosing.

Q: Can I give Nucala injections to myself at home?
A: Many adults and adolescents use prefilled syringes or autoinjectors at home after training from a healthcare provider, while younger children and those using the vial form typically receive injections in a clinic.

Q: Do I still need my inhalers or other medicines if I am on Nucala?
A: Yes, Nucala is an add-on therapy and does not replace your daily controller inhalers or quick‑relief inhalers or other prescribed medicines; any dose changes should be made only with your clinician’s guidance.

Q: Is Nucala safe during pregnancy or breastfeeding?
A: Data in pregnant and breastfeeding humans are limited, so decisions are individualized, balancing the importance of controlling eosinophilic disease against uncertain risks to the fetus or infant; this should be discussed in detail with your obstetric and specialty care providers.

Storage: Store Nucala prefilled syringes or autoinjectors in the refrigerator at 36°F to 46°F (2°C to 8°C), in the original carton to protect from light; do not freeze, do not shake, and keep away from heat.

Short-term out-of-fridge storage: If needed, an unopened carton can be kept at room temperature up to 86°F (30°C) for up to 7 days; any device left out longer than 7 days should be safely thrown away and not used.

After removing from the carton: Once a syringe or autoinjector is taken out of the carton, it should be used within 8 hours; if not used within 8 hours, it should be discarded and not put back in the refrigerator.

Disposal of medicine and supplies: Do not reuse Nucala devices and do not share them with others; place used syringes or autoinjectors in an FDA-cleared sharps disposal container and follow local or pharmacy instructions for throwing away full sharps containers and any expired or unused Nucala.

Safety at home: Always keep Nucala and sharps containers out of the sight and reach of children and pets.